An interventional study of Glow Shakes Premium Collagen Meal Replacement Intervention in Weight Management, Body Composition and Overweight, sponsored by The Collagen Co. - GLP-1 Users. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by The Collagen Co. - GLP-1 Users · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,484 studies in Overweight with a site in United States — 276 open to participants now, 403 under way, 69 of them phase 3. Overweight · United States.
Among the 1,484 studies in Overweight with a site in United States, this one is the 978th largest by planned enrollment of the 1,370 interventional ones that give a count, is one of 192 that started in 2026, is one of 916 with no phase, reaches primary completion later than 128 of the 401 other live ones, and was the 1,483rd registered.
3,620 studies on the registry are indexed under Overweight; 862 are open to participants now.
Browse Overweight studies →276 of the 1,484 studies in Overweight with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–70
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 535 Overweight studies recruiting now, 160 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,484 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 151 · Phase 2 178 · Phase 3 126 · Phase 4 31
First in 1983; this study’s year is marked. 192 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 78 across 3,139 interventional studies indexed under Overweight.
Median enrollment 85 across the 1,370 interventional studies, 126 across the 112 observational. Of the 1,019 that completed or were terminated, 248 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
385 of 1,484 have an industry lead sponsor. The 10 most frequent:
The Collagen Co. - GLP-1 Users is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
The Collagen Co. - GLP-1 Users has 1 study filed under Overweight — fewer than ten, so there is no comparison to draw.
158 of the studies in Overweight with a site in United States that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07298915Phase 3University of VirginiaThe Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) | 2026-12 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
Add all 158 to your calendar (.ics) → With an account.
Among the 1,484 studies in Overweight with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-group, open-label, decentralized clinical trial evaluating the effects of 6 weeks of daily Glow Shakes Premium Collagen Meal Replacement consumption on body composition, weight management, and self-reported health outcomes in 40 adults aged 18-55 years with a BMI between 25-35 kg/m².
All participants will consume Glow Shakes Premium Collagen Meal Replacement twice daily, replacing two typical meals, for 6 consecutive weeks. Assessments will be conducted at Baseline, Week 2, Week 4, and Week 6 and will include validated self-report questionnaires and body composition measurements via the Withings smart scale. All study activities are conducted remotely; products are shipped directly to participants' homes and all data are submitted digitally through the Citruslabs study platform.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Glow Shakes Premium Collagen Meal Replacement Intervention
All participants will consume Glow Shakes Premium Collagen Meal Replacement twice daily (replacing two meals) for 6 weeks. Assessments will be conducted at four timepoints: Baseline, Week 2, Week 4, and Week 6. Assessments will include validated self-report questionnaires and body composition measurements via the Withings smart scale.
Change in Body Weight
Change in body weight (kg) from Baseline to Week 6 as measured by the Withings smart scale (participant self-administered at home)
Time frame: Baseline to Week 6
Change in Body Fat Percentage
Change in body fat percentage (%) from Baseline to Week 6 as measured by the Withings smart scale (participant self-administered at home)
Time frame: Baseline to Week 6
Change in Self-Reported Weight Management Score
Change from Baseline in self-reported weight management scores as assessed via self-report questionnaire
Time frame: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Hunger Intensity
Change from Baseline in self-reported hunger intensity as assessed via self-report questionnaire
Time frame: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Satiety Duration
Change from Baseline in self-reported satiety duration as assessed via self-report questionnaire
Time frame: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Food Craving Score
Change from Baseline in self-reported food craving scores as assessed via the Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced)
Time frame: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Skin Health Score
Change from Baseline in self-reported skin health scores as assessed via self-report questionnaire
Time frame: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Hair Health Score
Change from Baseline in self-reported hair health scores as assessed via self-report questionnaire
Time frame: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Nail Health Score
Change from Baseline in self-reported nail health scores as assessed via self-report questionnaire
Time frame: Baseline, Week 2, Week 4, and Week 6
Change in Self-Reported Gut Comfort and Digestive Symptom Score
Change from Baseline in self-reported gut comfort and digestive symptom scores as assessed via self-report questionnaire
Time frame: Baseline, Week 2, Week 4, and Week 6
Participant-Reported Product Satisfaction
Participant-reported product satisfaction, acceptability, and tolerability as assessed via product satisfaction questionnaire
Time frame: Week 6
Participant-Reported Product Tolerability
Participant-reported tolerability of the study product as assessed via product satisfaction questionnaire
Time frame: Week 6
Participant-Reported Overall Product Experience
Participant-reported overall experience with the study product as assessed via product satisfaction questionnaire
Time frame: Week 6
Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.
Of 113 industry-sponsored interventional studies with no phase under Overweight, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 25. This study's planned 3 months is below that.
Counting every sponsor, half of 1,424 studies reached it within 17 months; a quarter within 7 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Collagen Co. - GLP-1 Users